Cardiovascular and renal benefits of empagliflozin and GLP-1 analogues

The aim of this American study was to compare the renal and cardiac efficacy of empagliflozin and cardioprotective GLP-1 analogues in patients at high cardiovascular risk. A total of 141,541 matched pairs were identified. Empagliflozin was associated with similar risks of myocardial infarction or stroke, but lower risks of heart failure, major cardiovascular events, cardiovascular mortality and end-stage renal disease. The differences observed between patients on empagliflozin or GLP-1 analogues were greatest in elderly patients and in patients with a history of coronary heart disease or heart failure. No difference was observed according to gender.